BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Illumina, Inc. (ILMN) Applies CE Mark to Expanded MiSeqDx™ System


9/25/2013 6:58:06 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Illumina Applies CE Mark to Expanded MiSeqDx™ System

SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (ILMN) today announced that it declared conformity with the requirements of the IVD Directive and has applied the CE mark to expand the use of the MiSeqDx system in clinical laboratories. These laboratories are now able to develop diagnostic tests using Illumina’s new MiSeqDx Universal Kit on the MiSeqDx. The MiSeqDx Universal Kit joins the MiSeqDx Cystic Fibrosis Carrier Screening Assay and the MiSeqDx Cystic Fibrosis Diagnostic Assay in Illumina’s expanding line of clinical products available for the MiSeqDx.

The MiSeqDx uses Illumina’s industry-leading sequencing by synthesis chemistry, the sequencing technology most widely adopted by genetics researchers worldwide. The instrument offers users the ability to run diagnostic or research applications on a single, easy-to-use system. The MiSeqDx Universal Kit includes the library preparation reagents, sample index primers, and sequencing consumables needed for laboratories to develop amplicon assays on an in vitro diagnostic platform.

“The MiSeqDx demonstrates Illumina’s continuing commitment to the clinical adoption of next-generation sequencing technologies. The company’s validated products provide reliability and flexibility to our clinical customers,” said Greg Heath, Senior Vice President and General Manager of Illumina’s Diagnostics business. “The MiSeqDx greatly expands the opportunity for clinical laboratories to offer diagnostic tests for wide-ranging applications including genetic and infectious diseases and cancer.”

The new functionality for the MiSeqDx, enabled by the MiSeqDx Universal Kit, will be commercialized in a number of European countries that require the CE mark, and will begin shipping in Europe beginning in November 2013. For more information, visit www.illumina.com/MiSeqDxPlatform.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected order availability date. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in developing and launching new products and services and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

Contact:

Illumina, Inc.

Investors:

Rebecca Chambers, 858-255-5243

rchambers@illumina.com

or

Media:

Jennifer Temple, 858-882-6822

pr@illumina.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES